Daily Newsletter

24 November 2023

Daily Newsletter

24 November 2023

Cambridge Memorial deploys AI tool for bone density screening

The tool leverages AI to analyse routine X-rays in patients aged 50 and above for low bone mineral density (BMD).

November 24 2023

Cambridge Memorial Hospital in Ontario, Canada, has partnered with 16 Bit to implement an artificial intelligence (AI)-powered tool called Rho.

The hospital is said to be the first in Ontario to adopt the solution for clinical use.

This Health Canada-approved system leverages AI to analyse routine X-rays in patients aged 50 and above for low BMD.

When low BMD is detected, the tool flags the X-ray for further review, aiding radiologists in identifying this condition earlier.

This early detection is aimed at facilitating timely preventive measures and treatments.

Rho aims to address the prevalence of low BMD, including osteopenia and osteoporosis, by identifying patients who may benefit from more specialised tests for bone density during routine X-ray exams. It can analyse 80% of all X-rays conducted.

The solution is said to be gaining popularity among independent healthcare facilities across Canada.

Rho has screened over 50,000 patients within its first year on the market, with a target of screening one million patients by the end of 2024.

Cambridge Memorial Hospital diagnostic imaging chief Dr Winnie Lee said: “Rho is a tool that will bring care closer to home and makes this advanced technology accessible to people in Cambridge, North Dumfries, and the Region of Waterloo.

“Good bone health contributes to overall quality of life. By acting early, we can help patients at risk of osteopenia lead full lives and avoid some of the fractures that might bring them to the hospital.”

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close